1. Market Research
  2. > Pathology
48 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Lymphoma Drugs Market 2017-2021

  • $ 2500
  • June 2017
  • 86 pages

The aim of lymphoma treatment is to get rid of the lymphoma cells.

  • Cancer
  • Lymphoma
  • Celgene Corporation
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

NHL: Mantle cell lymphoma

  • $ 5000
  • April 2016
  • 214 pages

Lymphoma Association (2016) Mantle cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Takeda Pharmaceutical Company Limited

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • August 2019
  • 228 pages

So the CAR T, for example, represents a cure of lymphoma and leukemia.

  • Blood Disease
  • Lymphoma
  • Pathology
  • Therapy
  • Takeda Pharmaceutical Company Limited

Nanopharmaceuticals - Thematic Research

  • $ 1950
  • March 2020
  • 96 pages

RAKUTEN MEDICAL IS HEADQUARTERED IN SAN DIEGO, CALIFORNIA, US. © GlobalData Abbreviations European Medicines Agency distearoylphosphatidylcholine dimethyl hydrazide diabetic macular edema diffuse large B-cell lymphoma cardiovascular Cutaneous T-cell lymphoma Complete Response Letter central

  • Lymphoma
  • Therapy
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Global Plasma Therapy Market (Pure PRP, Leukocyte-Rich PRP, Pure PRF, Leukocyte-Rich PRF): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

  • $ 1250
  • May 2020
  • 120 pages

Also, growing cases of general blood cancers like leukemia, myeloma and lymphoma are increasingly being observed in the US.

  • Lymphoma
  • Therapy
  • World
  • Market Size
  • Takeda Pharmaceutical Company Limited

Potential Pipeline Disruptors

  • $ 4200
  • May 2017
  • 120 pages

FOLLICULAR LYMPHOMA TENDS TO BE INDOLENT AND DIFFUSE LYMPHOMA TENDS TO BE AGGRESSIVE.

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Takeda Pharmaceutical Company Limited

Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Technology ; Application

  • $ 4550
  • April 2020
  • 177 pages

The liposome drug delivery market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019. The market is estimated to grow at a CAGR of 8.8% from 2020 to 2027. The growth of ...

  • Drug Delivery
  • Lymphoma
  • Topical Delivery
  • Forecast
  • Takeda Pharmaceutical Company Limited

Nanotechnology in Medicine - Thematic Research

  • $ 1950
  • June 2020
  • 28 pages

Nanotechnology in Medicine Thematic Research: Medical Nanotechnology in Medicine is on the Rise A persistent problem in medicine is the ability to specifically target diseased cells and tissues.

  • Lymphoma
  • Pharmaceutical
  • Janssen Biotech, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Ovarian Cancer Treatment Drugs Industry Forecasts - China Focus

  • $ 1800
  • May 2020
  • 136 pages

These compounds are used to treat a wide range of cancers, including leukemias, lymphomas, and breast, uterine, ovarian, and lung cancers.

  • Chemotherapy
  • Lymphoma
  • Therapy
  • China
  • Takeda Pharmaceutical Company Limited

Brain Cancer Treatment Drugs Industry Forecasts - China Focus

  • $ 1800
  • June 2020
  • 102 pages

Rather than controlling edema, steroids destroy lymphoma tumor cells, but they are not a long-time cure for this tumor.

  • Anti-Infective
  • Brain Cancer
  • Lymphoma
  • China
  • Takeda Pharmaceutical Company Limited

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

  • $ 513
  • November 2016
  • 75 pages

Rituxan is the first monoclonal antibody approved for lymphomas.

  • Lymphoma
  • Therapy
  • North America
  • United States
  • Takeda Pharmaceutical Company Limited

Artificial Intelligence Technologies: Market Prospects - Featuring Expert Panel Views from Industry Survey 2018

  • $ 2995
  • March 2018
  • 104 pages

Artificial Intelligence Technologies: Market Prospects - Featuring Expert Panel Views from Industry Survey 2018 Summary Artificial intelligence (AI) is defined as the theoretical and practical application ...

  • Advanced IT
  • Artificial Intelligence
  • Healthcare
  • Pharmaceutical
  • Takeda Pharmaceutical Company Limited

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease

  • $ 4995
  • December 2017
  • 160 pages

They also have an increased risk of Parkinson' s disease, and cancers such as myeloma, leukemia and lymphoma.

  • Clinical Trial
  • Genetic Disorder
  • Lymphoma
  • Therapy
  • Takeda Pharmaceutical Company Limited

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

  • $ 4995
  • September 2017
  • 137 pages

Numerous intracellular substrates such as insulin receptor substrate (IRS) proteins, casitas B-lineage lymphoma (CBL), adapter proteins with a pleckstrin homology (PH) and Src Homology ## (SH##) domain and GRB##-associated-binding protein ## (GAB##) are activated upon binding of the insulin rece

  • Clinical Trial
  • Diabetes
  • Insulin
  • Lymphoma
  • Takeda Pharmaceutical Company Limited

Global Antibody Drug Conjugates Market – Analysis By Drugs , Pipeline Drugs, Regulations: Opportunities and Forecasts - By Region ; By Country

  • $ 1800
  • March 2017
  • 154 pages

ACCORDING TO LYMPHOMA RESEARCH FOUNDATION THERE WERE AROUND ## PATIENTS SUFFERING FROM HODGKIN' S LYMPHOMA IN US.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • World
  • Takeda Pharmaceutical Company Limited

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

  • $ 4995
  • July 2017
  • 136 pages

In addition, the reported lymphoma cases were no greater than the expected rate in the general population (Munzenberger and Montejo, 2007).

  • Dermatological Condition
  • Dermatology
  • Lymphoma
  • Therapy
  • Takeda Pharmaceutical Company Limited

Global Next-Generation Biologics Market 2016-2020

  • $ 2500
  • November 2016
  • 124 pages

Its R& D division focuses on developing innovative drugs for the treatment of malignant lymphoma.

  • Cell Therapy
  • Lymphoma
  • Regenerative Medicine
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

Global Multiple Myeloma Drugs Market 2017-2021

  • $ 2500
  • December 2016
  • 86 pages

It is used in combination with rituximab, cyclophosphamide, prednisone, and doxorubicin for the treatment of adults with previously untreated mantle cell lymphoma.

  • Lymphoma
  • Therapy
  • Amgen Inc.
  • Celgene Corporation
  • Takeda Pharmaceutical Company Limited

Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

  • $ 4995
  • June 2017
  • 140 pages

Do RA and lymphoma share risk factors?

  • Autoimmune Disease
  • Immunology
  • Lymphoma
  • Therapy
  • Takeda Pharmaceutical Company Limited

Pharmaceutical Lifecycle Management Strategies in 2017

  • $ 2995
  • April 2017
  • 82 pages

HUMIRA RISANKIZUMAB Hidradenitis Suppurativa Uveitis Psoriasis Psoriatic Arthritis Crohn' s disease EMPLICITI VENCLEXTA Multiple myeloma second line Multiple myeloma first line Multiple myeloma Acute myeloid leukemia Follicular lymphoma Diffuse large B-cell lymphoma ELAGOLIX En

  • Lymphoma
  • Pharmaceutical
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
View report >

Lymphoma Statistics in the US

  • July 2017
  • 9 pages

These include studies in patients with relapsed or refractory Hodgkin lymphoma and CD##-expressing relapsed or refractory non-Hodgkin lymphomas, including T-cell lymphomas, diffuse large B-cell lymphoma (DLBCL), and other rare subtypes of Bcell malignancies, including mediastinal B-cell

  • Lymphoma
  • United States
  • Immunomedics, Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

Therapy Market January 2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on